Cardiac Extracellular Matrix From SUSD2-Selected Fibroblasts

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for isolating and culturing cardiac fibroblasts and myofibroblasts for cardiac extracellular matrix production lack specificity and efficiency, leading to non-specific cell types being included, which affects the quality and consistency of the matrix produced.

Innovation Solution

Selecting SUSD2 High fibroblasts and myofibroblasts from cardiac fibroblast populations and culturing them at a density of 100,000 to 500,000 cells per cm² to secrete a cardiac extracellular matrix, using SUSD2 as a marker for cell selection and ensuring high purity and matrix production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If simple morphometric geometry and plastic adherence are used to characterize cardiac fibroblasts and myofibroblasts, then the characterization process is simple and quick, but the identification is non-specific and includes other cell types such as mesenchymal stromal cells and pericytes

Engineering Contradiction:

Improveease of characterizationVSAvoidspecificity of cell identification

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent changes the characterization parameter from simple morphometric geometry and plastic adherence to SUSD2 protein expression level. This parameter change enables specific identification of cardiac fibroblasts and myofibroblasts while excluding other cell types, resolving the contradiction between ease of operation and measurement precision.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If cultured fibroblasts are used to produce extracellular matrix for tissue engineering, then the matrix can be used for therapeutic applications, but the quality and consistency of the matrix is affected by inclusion of non-specific cell types

Engineering Contradiction:

Improvetherapeutic utility of matrixVSAvoidquality and consistency of matrix

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent extracts and removes non-specific cell types (mesenchymal stromal cells, pericytes) from the fibroblast population through SUSD2-based identification and selection. This extraction ensures that only specific cardiac fibroblasts and myofibroblasts are used for matrix production, thereby improving the quality and consistency of the matrix while maintaining its therapeutic utility.

Inventive Principle:

Principle #2Taking out (Extraction)

3Productivity

If expanded investigations involving bioengineered matrices are conducted, then the therapeutic potential is explored, but careful characterization of cultured cells is required prior to scaling up manufacturing

Engineering Contradiction:

Improvescaling up of manufacturingVSAvoidcomplexity of cell characterization

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent replaces complex multi-parameter characterization methods with a single SUSD2-based identification system. This substitution simplifies the characterization process while maintaining the ability to ensure cell specificity and matrix quality, thereby enabling scaling up of manufacturing without excessive complexity.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS12419993B2Cardiac fibroblast derived extracellular matrix

Publication Date: 2025.09.23 WISCONSIN ALUMNI RES FOUND

AI summary

The disclosure generally relates to methods, cells, and compositions for preparing cardiac extracellular matrix. In particular, provided herein are methods for preparing a cardiac extracellular matrix using SUSD2 High fibroblasts and SUSD2 High myofibroblasts.